| Name | Tecadenoson |
| Description | Tecadenoson (CVT-510) is a selective A1 adenosine receptor agonist. |
| In vitro | Tecadenoson is approximately 5 fold more potent to prolong the stimulus-to-His bundle (S-H interval), a measure of slowing AV nodal conduction (EC50=41?nM) than to increase coronary conductance (EC50=200?nM) in the atrial-paced isolated heart. Tecadenoson shortens atrial (EC50=73?nM) but not the ventricular monophasic action potentials (MAP). At concentrations of Tecadenoson (40?nM) and diltiazem (1?μM) that induces equal prolongation of S-H interval (～10?ms), diltiazem, but not Tecadenoson, significantly decreases left ventricular developed pressure (LVP) and markedly increases coronary conductance [1]. |
| In vivo | Intravenous infusions of Tecadenoson and diltiazem causes nearly equal prolongations of P-R interval In atrial-paced anaesthetized guinea-pigs. Tecadenoson (2, 5, 20 μg/kg i.p.) causes a rapid and sustained dose-dependent decrease in NEFA at doses that do not cause bradycardia. Tecadenoson (50 μg/kg) treatment induces a significant bradycardia (50% decrease in heart rate at 25 min) [1][2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility Information | DMSO : 155 mg/mL (459.49 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (14.82 mM), Sonication is recommended.
|
| Keywords | Tecadenoson | P1 receptor | Inhibitor | inhibit | CVT510 | CVT 510 | AdenosineReceptor | Adenosine Receptor | A1 adenosine receptor | A1 |
| Inhibitors Related | Xanthine | Theophylline monohydrate | Diphylline | Adenosine monophosphate | Acefylline | Sulcatone | Adenosine 5'-monophosphate monohydrate | Inosine | Theobromine | Adenosine 5'-monophosphate disodium salt | Theophylline | Doxofylline |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
